With just 2 doses in 1 month1
Help protect your patients from HBV in a shorter period of time

2 doses of HEPLISAV-B provided earlier (3 months vs 7 months) and higher levels of protective immunity than 3 doses of Engerix-B® in patients aged 18-551,16

IN TRIAL 1: HEPLISAV-B seroprotection rates vs Engerix-B

Ages 18-55 immunity rates in trial 1 Ages 18-55 immunity rates in trial 1

*Protective immunity defined as antibody concentration ≥10 mIU/mL.

Engerix-B is a registered trademark of the GSK group of companies.



Study Results — Ages 18-55 (Trial 1)
HEPLISAV-B Hepatitis B Vaccine (Recombinant), Adjuvantedâ„¢ HEPLISAV-B Hepatitis B Vaccine (Recombinant), Adjuvantedâ„¢

Call 1-84-HEPLISAV (1-844-375-4728)
8 AM to 8 PM, ET, Monday through Friday